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Aim The effect of 8 weeks’ streptozotocin (STZ)-
induced diabetes and aminoguanidine (AMNG), the
inhibitor of advanced glycosylation reaction, treat-
ment on arteriolar reactivity to vasoactive substances
was investigated in vitro.
Materials and Methods Studies were performed in
untreated control rats (n=10), STZ-induced (60 mg/kg
i.v.) diabetic rats (n=10), AMNG-treated (600mg/1
given in drinking water throughout 8 weeks) control
rats (n=10) and AMNG-treated (600mg/1 given in
drinking water, beginning at 72h after STZ and
throughout 8 weeks of diabetes) diabetic rats (n=10).
Results are expressed as the mean 4-s.e. Relaxant
responses are expressed as a percentage (%) relaxa-
tion of noradrenaline-induced tone. Statistical com-
parisons were made by one-way analysis of variance
(ANOVA) followed by Tukey-Kramer multiple
comparisons test.
Results 1. The decreased body weights (205 4- 6g)
and increased blood glucose levels (583 4- 8 mg/dl) of
diabetic rats were partially restored by treatment of
aminoguanidine (253 4- 6 g, p < 0.05 and 480 4-14 mg/
dl, p < 0.001, respectively). 2. Diabetes caused a 71%
deficit in maximal endothelium-dependent relaxa-
tion to acetylcholine for noradrenaline precontracted
aortas (p<0.001). AMNG treatment prevented the
diabetes-induced impairment in endothelium de-
pendent relaxation (58 4- 8%) to acetylcholine, max-
imum relaxation remaining in the non-diabetic range
(78 4- 4%). 3. Neither diabetes nor treatment affected
endothelium-independent relaxation pD2 and max.
Relax.) to sodium nitroprusside. 4. Vasoconstrictor
responses pD2 and Max. Contraction) to noradrena-
line and KC1 were not influenced by the diabetic
state and treatment.
Conclusion Our data suggest that 8 weeks of
experimental diabetes is associated with a decreased
endothelium-dependent vasodilatation. AMNG
treatment may prevent diabetes-induced endothelial
dysfunction. This may be mediated via the preven-
tion of advanced glycosylation end product forma-
tion, the enhanced release of vasodilator substances
such as prostacyclin, the increased elasticity of blood
vessels, the antioxidant activity and inhibitor activity
of enzyme aldose-reductase by AMNG.
Keywords: Diabetes, aorta, streptozotocin, aminoguanidine,
endothelium
INTRODUCTION
Hyperglycaemia is the primary cause of diabetic
micro and macrovascular complications. I1"2J
Several major mechanisms have been proposed
for hyperglycaemia-induced tissue damage,
including advanced glycation end product
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(AGE) formation, altered intracellular redox (iii) AMNG-treated control group (AG-C)
state, increased polyol pathway flux, apoptosis (n 10),
and increased de novo diacylglycerol synthesis (iv) AMNG-treated diabetic group (AG + D)
with resultant activation of protein kinase C (n 10).
isoform.
[3- 7]
Studies on vascular reactivity using the STZ- Induction of Experimental Diabetes
diabetic rat have reported inconsistent results
with increased, decreased and unchanged re- Rats were injected intravenously (into the lateral
sponsiveness to noradrenaline, KC1, acetylcho- tail vein) with STZ (60mg/kg)(Sigma, S-0130,
line and sodium nitroprusside. E1-14 Lot. 128H1045). STZ was freshly prepared in
Today, in addition to the prevention of 0.25ml saline. The rats were then maintained for
hyperglycaemia by use of insulin and oral 8 weeks with free access to food and water.
hypoglycaemic agents, it has been also used Duration of the experimental period, blood
and tested some agent such as aminoguanidine glucose levels and body weights were measured
for the prevention and treatment of complica- beginning from 8th week.
tions in Diabetes Mellitus. Aminoguanidine is a
small, hydrazine compound structurally identi-
cal to the amino-terminal group of arginine and Aminoguanidine Treatment
several laboratories have reported beneficial The rats in group III (AMNG-treated control
effects of aminoguanidine in some diabetic group) and group IV (AMNG-treated STZ-
complications. The mechanisms for these effects diabetic group) were given 600 mg/1 AMNG in
of AMNG were accompanied by reduction of drinking water (in group AG + D, beginning at
advanced glycation end product (AGE) forma- 72h after STZ) for 8 weeks. The dosage in the
tion, the inhibition of an isoform of nitric oxide drinking water was three times lower for the
synthase (iNOS) and reactive oxygen species diabetic animals because their water intake is
(ROS) formation, lipid peroxidation and oxi- three times higher than that of nondiabetic
dant-induced apoptosis. E15-18 animals. [45] In the dosage calculation, followed
The present study was designed to define formula was used:
whether AMNG has beneficial effects on altered [(mg AG in per ml drinking waterxml
vascular reactivity of the thoracic aortas in daily water intake)]x[(1000/body weight)].
streptozotocin-diabetic rats.
MATERIALS AND METHODS
Animals
Albino Wistar rats were bred in our laborat-
ory and nourished ad libitum with standart
pellet diet and had free access to tap water.
Adult male and female Wistar rats (n=40),
weighing 200-300g, were divided into four
groups:
(i) Normal Control (= NC) (n 10),
(ii) STZ-diabetic group (= DC) (n 10),
Aortic Strips
Rats were sacrified by stunning followed by
decapitation. A segment (3-5cm) of thoracic
aorta was removed and placed in an ice-cold
Krebs-Ringer solution (KRS) of the following
composition (mmol/L): NaC1 (118), KC1 (4.7),
CaC12 (2.5), MgSO4.7H20 (1.2), KH2PO4 (1.2),
NaHCO3 and glucose (11.1) and then trimmed
free of adhering fat and connective tissue and
cut into rings of 3mm width. The rings were
opened by cutting the vessels longitudinally.
Subsequently, they were fixed with stainless
steel clips at both ends and then placed in 20mlEFFECT OF AMNG TREATMENT 147
organ baths containing KRS, gassed with carbo-
gen (95% 02+5% CO2) providing pH 7.4 at
37C. The preparation were connected to iso-
metric force displacement transducer (MAY,
FDT 10-A isometric transducer) connected to
MAY, TDA 97 polygraph and were equilibrated
for 90min at optimal resting tension of 2g.
During this time, the KRS in the organ bath was
replaced every 20 min.
Concentration-response Curves
After equilibration, the thoracic aorta strips were
exposed to 10-5mol/L ( EC90) noradrenaline
until the contraction reached the plateau (ap-
proximately 15 min) in order to measure the fast
and slow components of vascular response to
noradrenaline. The fast component was meas-
ured from the baseline to the point at which the
rate of contraction started to decrease abruptly.
The slow component was measured from
this point to the top of the contraction. The
total response was the sum of these two compo-
nents.
[16] Concentration-response curves were
obtained with noradrenaline. Noradrenaline
(10-9/3 10-9-10-4/3 10-4mol/L) was added
in a cumulative manner until a maximal re-
sponse was achieved. After the addition of each
dose, a plateau response was obtained before
the addition of a subsequent dose. Cumula-
tive relaxation curves to acetylcholine (Ach)
(10-8-10-4 mol/L) and sodium nitroprusside
(SNP) (10-8-104mol/L) were obtained in each
strip precontracted submaximally (approxi-
mately EC90, 10-5mol/L) by addition of nor-
adrenaline. Concentration-response curves were
obtained with KC1. KC1 (20, 40, 60 and 80
mmol/L) was added in a cumulative manner
until a maximal response was achieved. After
the addition of each dose, a plateau response
was obtained before the addition of a subse-
quent dose.
At the end of each experiment, tissue was
blotted dry, measured and weighed.
Data Analysis
Contractile responses to noradrenaline, KC1 and
relaxations to Ach (Inh.%) and SNP were
calculated as the increase (and decrease for
Ach and SNP) in tension (mg) in response to
the agonist per mg of aorta. Agonist pD2 value
(=-log EC50) was calculated from each agonist
concentration-response curve by linear regres-
sion analysis of the linear portion of the curve
and taken as a measure of the sensitivity of the
tissues to each agonist. All values are expressed
as (mean 4-SE). Statistical analysis of the data
was performed using one-way analysis of
variance (ANOVA) followed by Tukey-Kramer
Multiple comparisons test. p K 0.05 was consid-
ered as statistically significant.
RESULTS
General Characteristics
Data showing changes in body weight and final
blood glucose concentration for all groups are
summarized in Table I.
The body weights of diabetic rats (205 4- 7 g)
were significantly lower than NC (p < 0.001),
AG-C (p < 0.001) and AG+D (p < 0.05)
rats.
Eight weeks after injection, all rats treated
with STZ exhibited severe hyperglycaemia
and their blood glucose levels (583 4- 8mg/dl)
were significantly higher than those of NC
(p < 0.001), AG-C (p < 0.001) and AG+D
(p < 0.001)rats.
Water intakes and AG dosages were also
shown in Table I.
Agonist-induced Contractions
The contractile responses of aortic strips from all
groups are shown in Tables II and III. There
were no significant differences in contractile
responses, either pD2 or Emax. values, of aortic0EFFECT OF AMNG TREATMENT 149
TABLE II pD2 values in aortas from AMNG-treated and untreated control and diabetic rats
Groups n 10
pD2
NA Ach SNP KC1
Normal Control (NC)
Diabet Control (DC)
AMNG-Control (AG C)
AMNG-treated diabet (AG + D)
7.89 4- 0.20 6.53 4- 0.27 8.50 4- 0.26 1.52 4- 0.02
7.29 4- 0.46 5.69 4- 0.23 7.89 4- 0.21 1.63 4- 0.07
7.15 4- 0.18 5.93 4- 0.15 7.84 4- 0.23 1.44 4- 0.03
8.27 4- 0.28 6.33 4- 0.22 8.22 4- 0.17 1.60 4- 0.04
TABLE III Maximum contractions to NA and KC1 and maximum relaxations to Ach and SNP in diabetic and control rats
Emax. (mg tension/mg wet weight) % Max. relaxation
Groups n 10 NA KC1 Ach
Normal Control (NC)
Diabet Control (DC)
AMNG-Control (AG C)
AMNG-treated diabet (AG + D)
467 4- 29 237 4- 8 78 4- 4
425 4- 38 250 4- 20 23 4- 51’3
356 4- 15 221 4- 10 47 4- 82
342 4- 24 225 4- 5 58 4- 8
1DC vs. NC p < 0.001; 2NC vs. AG C p < 0.01" 3DC vs. AG+D p < 0.01.
TABLE IV The fast, slow and total components of contraction induced by noradrenaline in all the experimental groups
Groups n 10 Total Fast Slow
Normal Control (NC)
Diabet Control (DC)
AMNG-Control (AG C)
AMNG-treated diabet (AG + D)
450 4- 34 275 4- 20 175 4- 16
397 4- 54 232 4- 31 165 4- 25
370 4- 22 233 4- 18 137 4- 11
333 4- 26 216 4- 14 117 4- 13
strips to NA and KC1. In addition, as shown in
Table IV, either fast or slow components of
responses to noradrenaline were not signifi-
cantly different among all the experimental
groups.
Agonist-induced Relaxations
The acetylcholine-mediated relaxation (pD2 and
%Max. Relax.) of aortic strips precontracted with
NA is shown in Tables II and III. Either the
diabetic state or AMNG treatment had no effect
upon the pD2 pattern of relaxations in all groups.
In contrast, the maximum relaxations generated
by aortic strips from diabetic rats to Ach were
markedly smaller (p < 0.001) than those gener-
ated by corresponding control tissues (NC) from
age-matched rats. Treatment of diabetic animals
with AMNG prevented the diabetes-induced
depression of relaxations to Ach (DC vs. AG + D,
p < 0.01).
Table II illustrates the pD2 values for SNP
from all groups. It was observed that there were
no differences in the pD2 values among all the
experimental groups.
DISCUSSION
Vascular deterioration is one of the complicating
features of human and experimental diabetes
and hyperglycaemia is the primary cause of
diabetic micro and macro vascular complica-
tions. E’21 There are several variables which150 S. OZYAZGAN et al.
should perhaps be considered when comparing
results: strain of rat employed, drug employed
to induce diabetes, duration of diabetes, age of
animals, presence or absence of endothelium,
and the method used to calculate maximum
[10-14, 19, 20] response.
It has been shown that hyperglycaemia which
is one of the most important markers of diabetes,
caused tissue damage with several mechanisms,
including advanced glycation end product
(AGE) formation, increased polyol pathway
flux, apoptosis and reactive oxygen species
(ROS) formation. 3, 8, 9, 21] Endothelial dysfunc-
tion and impaired endothelium-dependent re-
laxations have been consistently demonstrated
with the histologic and experimental studies in
animal models of diabetes mellitus. [19,22-27] The
present results also demonstrated that in aortas
from STZ-diabetic rats, the endothelium-depen-
dent relaxant responses to Ach (25 4- 5%) was
significantly decreased compared with NC
(744-4%, p < 0.001) rats. Relaxation in the
AMNG treated-diabetic group (AG+D) was
significantly greater than that seen in the
diabetic control (DC) group and % Max. Relax.
values returned to near-control values (NC)
(58 4-8%). Our results are in agreement with
the majority of previous studies [22, 23- 27]
although others have reported no difference in
vascular responsiveness to Ach in diabetic
rats. [28,29] The endothelium-dependent relaxant
responses to agents such as acetylcholine are
largely due to release of endothelium derived
relaxing factor (EDRF). I301 EDRF is now
considered to be identical to nitric oxide which
is a key transducer of the vasodilator signal-
ling.
I30, 31] Impaired endothelium-dependent re-
laxation in STZ-induced diabetic rat might be
due to increased blood glucose level, decreased
blood insulin level, decreased influx of Ca
2+ into
endothelium or decreased release of Ca2+ from
its storage sites, a decreased content or inactiva-
tion of NO syntase and decreased diffusion of
NO into the smooth muscle. 581 In addition,
diabetes is believed to cause endothelial damage
via oxidative stress which induces ROS and lipid
peroxidation and a diabetes-induced functional
change in vascular endothelial cells could be a
key event in the development of the altered
endothelium-dependent vasoreactivity.
[32, 33]
AMNG used in this study is a potential
therapeutic agent for preventing the generation
of advanced glycation end products in diabetes
mellitus. [34] Although Crinjns et al. (1998) have
reported no beneficial effect of AMNG-treat-
ment, I451 Bucala et al. (1991) previously demon-
strated that acceleration of the advanced
glycosylation process in vivo results in a time-
dependent impairment in endothelium-depen-
dent relaxation and inhibition of advanced
glycosylation with aminoguanidine prevents
nitric oxide quenching, and ameliorates the
vasodilatory impairment. 35 These results agree
with our findings. In addition, a number have
suggested that AGEs decrease NO and cGMP
levels and vascular mechanical properties and
AMNG-treatment ameliorates this distur-
bances. I35, 36, 38] On the other hand,AMNG could
increase the release of vasodilator substances
such as prostacylin,
[37] and inhibit ROS forma-
tion [171 and oxidant-induced apoptosis. 181 An
alternative explanation for beneficial effect of
AMNG is its role on the polyol pathway. It has
been shown that polyol pathway is related with
the deficit for endothelium-dependent relaxation
and aldose reductase inhibitors can prevent this
deficit in aorta from STZ-diabetic rats
[131 and
Kumari et al., have recently demonstrated that
AMNG is an aldose reductase inhibitor. [39, 40]
The majority of previous studies showed that
the responsiveness to the endothelium-indepen-
dent vasodilator, SNP, is not impaired in
diabetics versus control [33’43-46] whilst some
[41,42] has demonstrated an impaired response.
This study have also showed an unchanged
sensitivity and a maximum relaxation to SNP in
diabetics. Our results agree with the majority of
previous studies. [33, 43-46]
The contractile response of the rat aorta to
noradrenaline, a nonselective alpha agonist,
is biphasic, consisting of a fast and a slow
component.47 The fast component of theEFFECT OF AMNG TREATMENT 151
contraction induced by noradrenaline is a
consequence of activation of alpha-1 adreno-
ceptors and has been demonstrated to be due
to mobilisation of intracellular calcium whereas
the slow component reflects activation of alpha-
2 adrenoceptors and is directly dependent upon
an influx of extracellular calcium. [48,49] Despite
the controversy concerning the effects of dia-
betes on the maximal response, sensitivity,
fast and slow components of response to the
alpha-adrenoceptor agonist, such as noradren-
aline,
[49-52] most studies agree that agonist
potency is not altered by diabetes. [20,53-55] The
present study has also demonstrated an un-
changed sensitivity, a maximum contraction and
its components to noradrenaline in diabetes.
Our results are in agreement with some of the
previous studies, t20, 53, 84, 58 The discrepancy
between our results and those of other groups
may be due to the different experiment proto-
cols. In the present study, there were also no
significant differences between the diabetic
tissues and control tissues in the responsiveness
to KC1. However, although some authors found
conflicting results, 56’57 the present results
[28,54] agree with those of other groups.
In conclusion, our study demonstrates that the
chronic AMNG-treatment reversed the dimin-
ished vascular relaxation. However, its exact
mechanism of action remain unclear and re-
quires further investigation.
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